A $7 Billion Fund Owns These Healthcare Stocks Now

Wall St. Watchdog reveals information regarding Los Angeles Capital Management’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 114 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $590.755 million.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011 reported holding 468,657 shares with a market value of $31,175,062. This comprised 0.71% of the total portfolio. On 09/30/2011 reported holding 932,133 shares with a market value of $59,367,549. This comprised 1.31% of the total portfolio. The net change in shares for this position over the two quarters is 463,476. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011 reported holding 1,170,547 shares with a market value of $24,113,269. This comprised 0.55% of the total portfolio. On 09/30/2011 reported holding 2,180,921 shares with a market value of $38,558,684. This comprised 0.85% of the total portfolio. The net change in shares for this position over the two quarters is 1,010,374. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011 reported holding 470,536 shares with a market value of $16,605,216. This comprised 0.38% of the total portfolio. On 09/30/2011 reported holding 1,162,945 shares with a market value of $38,028,302. This comprised 0.84% of the total portfolio. The net change in shares for this position over the two quarters is 692,409. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Baxter International Inc. (NYSE:BAX): On 06/30/2011 reported holding 48,194 shares with a market value of $2,876,700. This comprised 0.07% of the total portfolio. On 09/30/2011 reported holding 386,898 shares with a market value of $21,720,453. This comprised 0.48% of the total portfolio. The net change in shares for this position over the two quarters is 338,704. About Company: Baxter International Inc. develops, manufactures, and markets products and technologies related to hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. The Company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, and research laboratories.
  • The Cooper Companies Inc. (NYSE:COO): On 06/30/2011 reported holding 255,429 shares with a market value of $20,240,193. This comprised 0.46% of the total portfolio. On 09/30/2011 reported holding 267,060 shares with a market value of $21,137,799. This comprised 0.47% of the total portfolio. The net change in shares for this position over the two quarters is 11,631. About Company: The Cooper Companies, Inc. through its subsidiaries, develops, manufactures, and markets specialty healthcare products. The Company’s products include contact lenses for the vision care market and diagnostic products, surgical instruments, and accessories for gynecologists and obstetricians.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011 reported holding 170,690 shares with a market value of $6,405,995. This comprised 0.15% of the total portfolio. On 09/30/2011 reported holding 561,419 shares with a market value of $20,755,661. This comprised 0.46% of the total portfolio. The net change in shares for this position over the two quarters is 390,729. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011 reported holding 175,008 shares with a market value of $9,208,921. This comprised 0.21% of the total portfolio. On 09/30/2011 reported holding 403,550 shares with a market value of $20,637,547. This comprised 0.46% of the total portfolio. The net change in shares for this position over the two quarters is 228,542. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Wellpoint Inc. (NYSE:WLP): On 06/30/2011 reported holding 31,233 shares with a market value of $2,460,223. This comprised 0.06% of the total portfolio. On 09/30/2011 reported holding 308,535 shares with a market value of $20,141,164. This comprised 0.45% of the total portfolio. The net change in shares for this position over the two quarters is 277,302. About Company: WellPoint Inc. is a health benefits company. The Company provides health benefits, dental and vision benefits, pharmacy benefits, life insurance, and life and disability insurance benefits. WellPoint operations include Blue Cross and Blue Shield plans.
  • Biogen Idec Inc. (NASDAQ:BIIB): On 06/30/2011 reported holding 86,510 shares with a market value of $9,249,649. This comprised 0.21% of the total portfolio. On 09/30/2011 reported holding 192,323 shares with a market value of $17,914,888. This comprised 0.4% of the total portfolio. The net change in shares for this position over the two quarters is 105,813. About Company: Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company’s products addresses diseases such as multiple sclerosis, non-Hodgkin’s lymphoma, rheumatoid arthritis, crohn’s disease, and psoriasis.
  • Mednax Inc. (NYSE:MD): On 06/30/2011 reported holding 271,531 shares with a market value of $19,601,824. This comprised 0.44% of the total portfolio. On 09/30/2011 reported holding 250,953 shares with a market value of $15,719,696. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is -20,578. About Company: MEDNAX, Inc., through a subsidiary, provides physician management services to hospital-based neonatal, maternal – fetal, pediatric cardiology, and pediatric intensive care specialties. The Company also manages anesthesia practices.

(Note: Data regarding Los Angeles Capital Management’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>